The First EASL Nonalcoholic Fatty Liver Disease (NAFLD) Summit: “Target-oriented approach to Diagnosis and Pharmacotherapy of Nonalcoholic Steatohepatitis (NASH), a dialogue between Academia and Industry” was held last week in Rome.
ProSciento´s CEO, Dr. Marcus Hompesch, presented a work in collaboration with OWL Metabolomics, describing the latest updates on the application of a non-invasive integrated biomarker screening approach (NIBS) to facilitate enrollment in clinical trials with investigational therapeutics for NAFLD/NASH.
Link:
www.easl.eu/discover/events/detail/2017/first-easl-nafld-summit-target-oriented-approach-to-diagnosis-and-pharmacotherapy-of-nash-a-dialogue-between-academia-and-industry
Descargar archivo
A través de su web, OWL pretende contribuir a la divulgación de la ciencia y a la mejora de la salud y el bienestar de las personas. El carácter de la web esmeramente divulgativo y en ningún caso puede sustituir la relación médico-paciente. Ante cualquier duda, acuda a su centro médico o especialista.Última actualización: 19/10/2021